Details for Patent: 10,772,883

« Back to Dashboard

Which drugs does patent 10,772,883 protect, and when does it expire?

Patent 10,772,883 protects TYVASO DPI and is included in one NDA.

This patent has thirty-one patent family members in sixteen countries.

Summary for Patent: 10,772,883

Title:	Diketopiperazine microparticles with defined specific surface areas
Abstract:	Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Inventor(s):	Marshall L. Grant, Grayson W. Stowell, Paul Menkin, John J. Freeman, Jr.
Assignee:	Mannkind Corp
Application Number:	US15/462,559
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Delivery;

Drugs Protected by US Patent 10,772,883

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022		RX	Yes	Yes			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-002	May 23, 2022		RX	Yes	Yes			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-003	May 23, 2022		RX	Yes	Yes			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-004	May 23, 2022		RX	Yes	Yes			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024		RX	Yes	Yes			Y

International Family Members for US Patent 10,772,883

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077086
Australia	2010259943
Brazil	PI1013154
Canada	2764505
China	102647979
China	104721825